Using computers to make a digital replica of the heart – a digital heart twin – can successfully identify problem areas deep ...

In that single-arm study, the rate of primary adverse events within 7 days of ablation was 2.9%, with the most common ...

Solid Biosciences advances gene therapies for muscular and cardiac diseases, gaining FDA clearance for SGT-212 and targeting ...

A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events ...

Truist launched its coverage of gene therapy developer Solid Biosciences (NASDAQ:SLDB) on Wednesday with a Buy recommendation ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.